MX2012014387A - Dispersiones solidas que contienen inhibidores de cinasa. - Google Patents

Dispersiones solidas que contienen inhibidores de cinasa.

Info

Publication number
MX2012014387A
MX2012014387A MX2012014387A MX2012014387A MX2012014387A MX 2012014387 A MX2012014387 A MX 2012014387A MX 2012014387 A MX2012014387 A MX 2012014387A MX 2012014387 A MX2012014387 A MX 2012014387A MX 2012014387 A MX2012014387 A MX 2012014387A
Authority
MX
Mexico
Prior art keywords
surfactant
polymeric carrier
compound
kinase inhibitors
solid dispersion
Prior art date
Application number
MX2012014387A
Other languages
English (en)
Inventor
Jonathan Miller
Yi Gao
Eric A Schmitt
Rajeev Gokhale
Justin Lafountaine
Lloyd Dias
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44475097&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2012014387(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of MX2012014387A publication Critical patent/MX2012014387A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4743—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Se describe una dispersión sólida que comprende, en forma esencialmente no cristalina, un compuesto inhibidor de cinasa, por ejemplo N-(4-{4-amino-7-[1-(2-hidroxietil)-1H-pirazol-4-il]tie no[3, 2-c] piridin-3-iI}fenil)N'-(3-fluorofeniI)urea, disperso en una matriz sólida que comprende (a) un transportador polimérico soluble en agua farmacéuticamente aceptable y (b) un tensoactivo farmacéuticamente aceptable. Un proceso para preparar una dispersión sólida, en donde el proceso comprende disolver el compuesto, el transportador polimérico y el tensoactivo y tener el compuesto disperso en el mismo, en forma esencialmente no cristalina. La dispersión sólida es adecuada para administración oral a un sujeto que necesita de tratamiento para un cáncer.
MX2012014387A 2010-06-09 2011-06-07 Dispersiones solidas que contienen inhibidores de cinasa. MX2012014387A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35286210P 2010-06-09 2010-06-09
PCT/US2011/039430 WO2011156361A2 (en) 2010-06-09 2011-06-07 Solid dispersions containing kinase inhibitors

Publications (1)

Publication Number Publication Date
MX2012014387A true MX2012014387A (es) 2013-05-01

Family

ID=44475097

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012014387A MX2012014387A (es) 2010-06-09 2011-06-07 Dispersiones solidas que contienen inhibidores de cinasa.

Country Status (27)

Country Link
US (1) US8557995B2 (es)
EP (1) EP2579855B1 (es)
JP (1) JP5758486B2 (es)
KR (1) KR20130109092A (es)
CN (1) CN103002880B (es)
AR (1) AR081845A1 (es)
AU (1) AU2011264993B2 (es)
BR (1) BR112012031516A2 (es)
CA (1) CA2802021A1 (es)
CL (1) CL2012003446A1 (es)
CO (1) CO6640325A2 (es)
CR (1) CR20120647A (es)
DO (1) DOP2012000306A (es)
EC (1) ECSP13012364A (es)
ES (1) ES2523999T3 (es)
GT (1) GT201200333A (es)
HK (1) HK1182327A1 (es)
MX (1) MX2012014387A (es)
NZ (1) NZ605434A (es)
PE (1) PE20130231A1 (es)
RU (1) RU2566716C2 (es)
SG (2) SG2014013502A (es)
TW (1) TW201202234A (es)
UA (1) UA108886C2 (es)
UY (1) UY33437A (es)
WO (1) WO2011156361A2 (es)
ZA (1) ZA201300108B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150000869A (ko) * 2011-12-14 2015-01-05 애브비 인코포레이티드 키나제 억제제를 함유하는 조성물
WO2014024210A2 (en) * 2012-08-10 2014-02-13 Hetero Research Foundation Novel polymorphs of doxercalciferol
KR101986683B1 (ko) * 2012-12-13 2019-06-10 한미약품 주식회사 테트라졸 유도체를 활성 성분으로 포함하는 용해도가 개선된 고체 분산체
US9249134B2 (en) * 2013-03-26 2016-02-02 Cadila Healthcare Limited Process for preparation of amorphous form of dasatinib
CN105307636A (zh) * 2013-07-19 2016-02-03 西佳技术公司 非晶形特考韦瑞制备
EP3089736A4 (en) * 2013-12-31 2017-08-23 Ascendia Pharmaceuticals, LLC Pharmaceutical compositions for poorly water-soluble compounds
WO2015141662A1 (ja) * 2014-03-18 2015-09-24 武田薬品工業株式会社 固体分散体
WO2015152433A1 (en) * 2014-03-31 2015-10-08 Hanmi Pharm. Co., Ltd. Amorphous solid dispersion comprising paclitaxel, tablet comprising the same, and method for preparing the same
US20170197980A1 (en) * 2014-06-25 2017-07-13 Abbvie Inc. N-(4-phenyl)-n'-(3-fluorophenyl)urea docusate
WO2016193860A1 (en) * 2015-06-04 2016-12-08 Pfizer Inc. Solid dosage forms of palbociclib
CN105816437B (zh) * 2016-03-29 2018-08-03 深圳市药欣生物科技有限公司 一种帕布昔利布的药物制剂及其制备方法
US10449195B2 (en) 2016-03-29 2019-10-22 Shenzhen Pharmacin Co., Ltd. Pharmaceutical formulation of palbociclib and a preparation method thereof
US20220409548A1 (en) 2019-03-04 2022-12-29 Japan Tobacco Inc. Amorphous solid dispersion of pyrazole-amide compound
CN110946829A (zh) * 2019-12-30 2020-04-03 上海景峰制药有限公司 一种阿瑞匹坦固体分散体及其制备方法和应用
CA3168667A1 (en) 2020-01-24 2021-07-29 Nanocopoeia, Llc Amorphous solid dispersions of dasatinib and uses thereof
AU2021212258A1 (en) 2020-01-31 2022-09-29 Nanocopoeia, Llc Amorphous nilotinib microparticles and uses thereof
EP4142699A1 (en) 2020-04-30 2023-03-08 Nanocopoeia LLC Orally disintegrating tablet comprising amorphous solid dispersion of nilotinib
CN114306245A (zh) 2020-09-29 2022-04-12 深圳市药欣生物科技有限公司 无定形固体分散体的药物组合物及其制备方法
WO2023283616A1 (en) * 2021-07-09 2023-01-12 Regents Of The University Of Minnesota Amorphous solid dispersion of sorafenib and solid formualtion comprising the same
NL2028762B1 (en) * 2021-07-16 2023-01-23 Seranovo Holding B V Micelle-generating formulations for enhanced bioavailability
US11980619B2 (en) 2021-07-28 2024-05-14 Nanocopoeia, Llc Pharmaceutical compositions and crushable tablets including amorphous solid dispersions of dasatinib and uses

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2287971T3 (es) 1997-08-11 2007-12-16 Pfizer Products Inc. Dispersiones farmaceuticas solidas con biodisponibilidad incrementada.
SI1450799T1 (sl) * 2001-12-03 2007-02-28 Bayer Pharmaceuticals Corp Aril secninske spojine v kombinaciji z drugimi citostaticnimi ali citotoksicnimi sredstvi za zdravljenje cloveskih rakov
BR0307516A (pt) 2002-02-01 2004-12-07 Pfizer Prod Inc Formas de dosagem de liberação imediata contendo dispersões de uma droga sólida
KR100758045B1 (ko) 2002-02-01 2007-09-11 화이자 프로덕츠 인크. 압력 노즐을 이용하여 균질한 분무 건조된 비결정질 고체약물 분산제를 제조하는 방법
CA2472028C (en) 2002-02-01 2010-03-30 Pfizer Products Inc. Method for making homogeneous spray-dried solid amorphous drug dispersions utilizing modified spray-drying apparatus
US7202363B2 (en) 2003-07-24 2007-04-10 Abbott Laboratories Thienopyridine and furopyridine kinase inhibitors
CL2004001884A1 (es) 2003-08-04 2005-06-03 Pfizer Prod Inc Procedimiento de secado por pulverizacion para la formacion de dispersiones solidas amorfas de un farmaco y polimeros.
MY191349A (en) * 2004-08-27 2022-06-17 Bayer Pharmaceuticals Corp New pharmaceutical compositions for the treatment of hyper-proliferative disorders
CN101048140B (zh) 2004-08-27 2013-06-19 拜尔保健公司 用于治疗癌症的药物组合物
US8834929B2 (en) 2006-07-21 2014-09-16 Bend Research, Inc. Drying of drug-containing particles
US20100143459A1 (en) * 2006-11-09 2010-06-10 Abbott Gmbh & Co. Kg Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor
EP2197425A2 (en) * 2007-10-19 2010-06-23 Abbott GmbH & Co. KG Solid dispersion product of n-aryl urea-based drugs
EP2346495B2 (en) 2008-10-07 2023-05-24 Kudos Pharmaceuticals Limited Pharmaceutical formulation 514
WO2010065825A2 (en) * 2008-12-05 2010-06-10 Abbott Laboratories Kinase inhibitors with improved cyp safety profile
TWI532484B (zh) 2009-06-08 2016-05-11 艾伯維有限公司 包含凋亡促進劑之固態分散劑
TWI471321B (zh) 2009-06-08 2015-02-01 Abbott Gmbh & Co Kg Ｂｃｌ－２族群抑制劑之口服醫藥劑型

Also Published As

Publication number Publication date
ZA201300108B (en) 2013-09-25
AU2011264993B2 (en) 2014-02-06
AR081845A1 (es) 2012-10-24
SG186248A1 (en) 2013-01-30
EP2579855B1 (en) 2014-09-03
AU2011264993A1 (en) 2013-01-24
CA2802021A1 (en) 2011-12-15
NZ605434A (en) 2014-03-28
ECSP13012364A (es) 2013-01-31
GT201200333A (es) 2014-06-10
KR20130109092A (ko) 2013-10-07
ES2523999T3 (es) 2014-12-03
JP5758486B2 (ja) 2015-08-05
DOP2012000306A (es) 2013-01-31
WO2011156361A2 (en) 2011-12-15
CR20120647A (es) 2013-04-08
CN103002880A (zh) 2013-03-27
US8557995B2 (en) 2013-10-15
US20110306632A1 (en) 2011-12-15
PE20130231A1 (es) 2013-04-04
SG2014013502A (en) 2014-05-29
TW201202234A (en) 2012-01-16
RU2566716C2 (ru) 2015-10-27
WO2011156361A3 (en) 2012-07-05
HK1182327A1 (en) 2013-11-29
JP2013528218A (ja) 2013-07-08
BR112012031516A2 (pt) 2016-11-08
UA108886C2 (ru) 2015-06-25
CN103002880B (zh) 2015-01-28
EP2579855A2 (en) 2013-04-17
CL2012003446A1 (es) 2013-04-05
CO6640325A2 (es) 2013-03-22
RU2012156254A (ru) 2014-07-20
UY33437A (es) 2012-01-31

Similar Documents

Publication Publication Date Title
MX2012014387A (es) Dispersiones solidas que contienen inhibidores de cinasa.
SA515360229B1 (ar) مثبطات‎ ‎عامل التمايز والنمو 8‏
MX2010009163A (es) Derivados heterociclicos de urea y metodos de uso de los mismos-211.
WO2006081252A3 (en) Use of 1-benzyl-1-hydr0xy-2, 3-diamino-propyl amines, 3-benzyl-3-hydroxy-2-amino-propionic acid amides and related compounds as analgesics
MX2012014017A (es) Derivados de heteroaril imidazolona como inhibidores de jak.
NZ603364A (en) Inhibitors of arginase and their therapeutic applications
MX347544B (es) Antagonista de acido lisofostatidico 1 (lpa1) policiclico y usos del mismo.
IL205697A0 (en) 4(-3-(-2-(phenyl)morpholino)-2-oxopyrrolidin-1-yl)-n-(thiazole-2-yl)benzenesulfon-amide derivatives, compositions comprising the same and uses thereof
NZ592714A (en) Thieno[3,2-c]pyridine derivatives as kinase inhibitors for use in the treatment of cancer
WO2008019372A3 (en) 2-aminobenzoxazole carboxamides as 5ht3 modulators
MX368747B (es) Parche no acuoso de lidocaína y un agente de disolución que comprende un ácido orgánico y un polialcohol que están contenidos en un emplaste para usarse en el tratamiento de dolor muscular a través de la piel.
GEP20186880B (en) 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease
WO2018060463A3 (en) Treatment of prostate cancer
MX2012014386A (es) Formas cristalinas de inhibidores de cinasa.
MX2010009756A (es) Agonistas de receptores muscarinicos, composiciones, metodos de tratamiento de los mismos, y proceso para preparacion de los mismos.
IL209270A (en) Compounds containing tricyclic nitrogen and their use as antibacterial
MX2015012896A (es) Inhibidores de pirrolo [2,3-b] piridina cdk9 cinasa.
PH12017501750A1 (en) 6-morpholinyl-2-pyrazolyl-9h-purine derivatives and their use as pi3k inhibitors
PH12014501333A1 (en) Compositions containing kinase inhibitors
MX2012014348A (es) Formas cristalinas de inhibidores de cinasa.
MX2012014385A (es) Formas cristalinas de inhibidores de cinasa.
EA201000889A1 (ru) Тризамещенные пиперидины в качестве ингибиторов ренина
TH139647A (th) สารกระจายชนิดแข็งที่ประกอบด้วยสารยับยั้งไคเนส (solid dispersions containing kinase inhibitors)
WO2011133475A3 (en) Compositions and method for the treatment of multiple myeloma
UA102694C2 (ru) Трициклические азотсодержащие соединения и их применение как бактерицидных средств

Legal Events

Date Code Title Description
FG Grant or registration